Verona Pharma plc
VRNADelisted Oct 7, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001657312
Verona Pharma plc was delisted on Oct 7, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 243 institutions reported holding it in 13F filings for Q3 2025, worth $8.57B in total; superinvestors Duquesne Family Office and Soros Fund Management held it.
13F holders, Q2 2021
Institutional positions in Verona Pharma plc as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 37
- 0 vs. Q1 2021
- Shares held
- 36.7M
- +168.7K (+0.5%) vs. Q1 2021
- Total value
- $239.9M
- −$65.2M (−21.4%) vs. Q1 2021
- New holders
- 6
- 5 more added
- Sold out
- 6
- 6 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VRNA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 1 | $359.0K |
| Q3 2025 | 243 | $8.57B |
| Q2 2025 | 292 | $7.18B |
| Q1 2025 | 258 | $4.58B |
| Q4 2024 | 191 | $3.19B |
| Q3 2024 | 150 | $1.95B |
| Q2 2024 | 125 | $957.0M |
| Q1 2024 | 113 | $1.08B |
| Q4 2023 | 117 | $1.35B |
| Q3 2023 | 102 | $1.07B |
| Q2 2023 | 105 | $1.33B |
| Q1 2023 | 95 | $1.21B |
| Q4 2022 | 88 | $1.31B |
| Q3 2022 | 68 | $529.0M |
| Q2 2022 | 40 | $145.9M |
| Q1 2022 | 39 | $181.7M |
| Q4 2021 | 42 | $248.0M |
| Q3 2021 | 40 | $202.7M |
| Q2 2021 | 37 | $239.9M |
| Q1 2021 | 37 | $305.1M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Verona Pharma plc; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Barclays PLC | 10 | $0 | 0.00% | −100−90.9% | Reduced |
| Deutsche Bank AG | 58 | $0 | 0.00% | +58 | New |
| Fifth Third Bancorp | 1,000 | $7.00K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,365 | $9.00K | 0.00% | +1,365 | New |
| Endurance Wealth Management, Inc. | 2,000 | $12.0K | 0.00% | 00.0% | Unchanged |
| Parallel Advisors, LLC | 2,000 | $13.0K | 0.00% | +2,000 | New |
| Bank of America Corp | 3,355 | $22.0K | 0.00% | +3,355 | New |
| Morgan Stanley | 3,674 | $24.0K | 0.00% | +2,174+144.9% | Added |
| US Bancorp | 3,840 | $25.0K | 0.00% | 00.0% | Unchanged |
| Brewin Dolphin Ltd | 4,415 | $28.9K | 0.00% | 00.0% | Unchanged |
| Chicago Partners Investment Group LLC | 10,006 | $58.0K | 0.00% | +10,006 | New |
| Rathbone Brothers plc | 11,959 | $78.0K | 0.00% | 00.0% | Unchanged |
| Quantitative Systematic Strategies LLC | 14,034 | $92.0K | 0.03% | −15,136−51.9% | Reduced |
| HSBC Holdings PLC | 15,041 | $101.0K | 0.00% | 00.0% | Unchanged |
| Forefront Analytics, LLC | 15,506 | $104.0K | 0.04% | +1,404+10.0% | Added |
| Wedbush Securities Inc | 18,035 | $118.0K | 0.01% | −3,965−18.0% | Reduced |
| IHT Wealth Management, LLC | 18,560 | $121.0K | 0.01% | −130−0.7% | Reduced |
| D.A. Davidson & Co. | 41,900 | $274.0K | 0.00% | 00.0% | Unchanged |
| Schonfeld Strategic Advisors LLC | 58,200 | $381.0K | 0.00% | +1,700+3.0% | Added |
| Fairmount Funds Management LLC | 83,944 | $549.0K | 0.23% | 00.0% | Unchanged |
| venBio Partners LLC | 161,897 | $1.06M | 0.12% | 00.0% | Unchanged |
| BlackRock Inc. | 249,941 | $1.64M | 0.00% | +249,941 | New |
| Tekla Capital Management LLC | 751,905 | $4.92M | 0.16% | 00.0% | Unchanged |
| Novo Holdings A/S | 761,205 | $4.98M | 0.22% | −77,155−9.2% | Reduced |
| Sphera Funds Management Ltd. | 801,256 | $5.24M | 0.50% | 00.0% | Unchanged |
| Polar Capital Holdings Plc | 900,000 | $5.89M | 0.03% | −100,000−10.0% | Reduced |
| Ghost Tree Capital, LLC | 1,000,000 | $6.54M | 2.05% | +60,957+6.5% | Added |
| Foresite Capital Management III, LLC | 1,111,112 | $7.27M | 7.70% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 1,111,112 | $7.27M | 0.96% | 00.0% | Unchanged |
| Aisling Capital Management LP | 1,332,485 | $8.71M | 1.40% | 00.0% | Unchanged |
| Abingworth LLP | 2,457,499 | $16.0M | 4.95% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 2,888,889 | $18.9M | 0.25% | 00.0% | Unchanged |
| Vivo Capital, LLC | 3,048,507 | $19.9M | 0.86% | 00.0% | Unchanged |
| Wellington Management Group LLP | 3,911,840 | $25.6M | 0.00% | +113,699+3.0% | Added |
| Ra Capital Management, L.P. | 5,100,000 | $33.4M | 0.54% | 00.0% | Unchanged |
| NEA Management Company, LLC | 5,108,563 | $33.4M | 0.44% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 5,694,841 | $37.2M | 0.38% | 00.0% | Unchanged |
| HighVista Strategies LLC | 0 | $0 | 0.00% | −36,638−100.0% | Sold out |
| DAFNA Capital Management LLC | 0 | $0 | 0.00% | −18,337−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −15,035−100.0% | Sold out |
| Personal Cfo Solutions, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −1,407−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −35−100.0% | Sold out |